Helen Gordon will leave the RPS next year to become the chief executive of The Royal Society of Medicine. Helen remains in post at RPS until February 2017 and will join the RSM in March. She joined the Royal Pharmaceutical Society in July 2010 and developed its role, work and impact as the newly dedicated professional body for pharmacists after the organisation split from its regulatory function that year. She has championed the introduction of a professional development and recognition system for pharmacists, the RPS Faculty and Foundation programmes, published professional standards as well as guidance and has increased the profile and contribution of the RPS to international pharmacy.
Irina Antonijevic has been appointed chief medical officer of vasopharm, a private German biopharmaceutical company focused on novel therapeutics for the treatment of cerebrovascular diseases. Irina has more than 15 years of global drug development experience in neuroscience, both in neurology and psychiatry, having held positions at Schering and Lundbeck Research in the US. She previously was global head of early development in neurology, multiple sclerosis and ophthalmology at Sanofi Genzyme, Cambridge, USA.
Ken James, who joined Futura Medical as a non-executive director in March, is now joining the company’s executive team as an executive director and head of R&D. Ken is the former head of consumer healthcare R&D at GlaxoSmithKline, where he brought more than 200 innovative products to market. In the newly created role of head of R&D, he will oversee the development, regulatory and manufacturing strategies for the company’s existing pipeline of products and the evaluation of earlier stage pipeline opportunities.
Artios Pharma has appointed Simon Boulton as VP science strategy. Simon is an award-winning British scientist at the Francis Crick Institute who has made important contributions over the past 20 years to the understanding of DNA repair and the treatment of cancer resulting from DNA damage. As a result of his ground-breaking work, Simon has received a number of prestigious accolades, notably the EMBO Gold Medal and the Paul Marks Prize for Cancer Research. In addition to his current role at the Francis Crick Institute, Simon is an honorary professor at University College London, an elected member of EMBO and a fellow of the Academy of Medical Sciences.
Anke Linnartz has joined MorphoSys as VP and head of corporate communications and investor relations. Anke joins MorphoSys from Gerresheimer, where she headed the investor relations and creditor relations department from 2008 to 2016. Prior to that, she was in charge of the capital markets communications at German M-DAX company Demag Cranes. Before that, she headed the capital markets communications of GEA Group, managing the communications of a transformative group restructuring process.
Mereo BioPharma has appointed Richard Jones as CFO. Richard joins Mereo from Shield Therapeutics where he has been CFO and company secretary. He was initially appointed as a non-executive director at Shield in 2010 before moving to his current position in 2011 where he had a leading role establishing the finance operations and guiding Shield through its recent IPO. Prior to this, Richard had a career in investment banking, holding senior positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs and M&A.
Norwegian immuno-oncology specialist Targovax has appointed Oystein Soug as its new chief executive officer following the resignation of Gunnar Gåardemyr. Formerly chief financial officer, Soug joined Targovax in 2015 bringing over 20 years of financial management experience to the role. He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods company.
CRO Metrion Biosciences has appointed Andrew Southan as head of commercial operations. Andrew joins from Charles River Laboratories where he served as director of ion channel biology. He previously served as group lead for BioFocus' ion channel team, head of electrophysiology for Ionix Pharmaceuticals, and also brings experience from CeNeS Pharmaceuticals and Wyeth Research UK.
Former Roche CEO and chairman Franz Humer has joined Arix Bioscience as a senior independent director. Franz joined Roche as head of pharmaceuticals in 1995 before becoming chief operating officer in 1996. He is currently chairman of Diageo, a consumer goods company, and a non-executive director of Chugai Pharmaceuticals, Citigroup and Kite Pharma.
inVentiv Health Communications has appointed Julie Adrian as managing director for its European operations. Julie will oversee the group's advertising, digital, public relations, medical communications, research, market access and clinical trial recruitment agencies across London, Frankfurt, Munich and Paris. For the last 13 years, she served as US managing director for Chandler Chicco Agency, and prior to this was executive vice president of Cohn & Wolfe in New York. She also brings pharmaceutical communications experience from Sanofi, where she was US product communications manager from 1997 to 1999.
PureTech Health has appointed Joseph Bolen as its chief scientific officer. Joseph will be responsible for the scientific development and advancement of PureTech Health's pipeline, working with the company's scientific advisory board and R&D team. Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer. Prior to this, he was chief scientific officer and global head of oncology research at Millennium, Takeda's oncology business, and has held senior R&D positions at Bristol-Myers Squibb, Hoechst Marion Roussel and Schering-Plough.
Anti-infectives company Auspherix has announced further strengthening of its management team, with Neil Miller transitioning to chief executive officer (CEO) from chief scientific officer (CSO), and the company announcing two new appointments of Richard Rutter as CSO and Paul King as head of chemistry. Neil has served as CSO of Auspherix over the past 12 months, having previously gained two decades of experience working at GSK. An expert pharmacologist and biologist with over 15 years of industry experience, Richard joins the company as the new CSO. Prior to his role at Auspherix, Richard was the head of biology at GSK's Neuroscience R&D Centre in Singapore. A medicinal chemist, Paul joins Auspherix as head of chemistry. Prior to his appointment at Auspherix, Paul also held a number of positions at GlaxoSmithKline, including team and programme leader in the Neural Pathways Discovery Performance Unit, Singapore.
UK disease management diagnostics firm Glyconics has appointed Kam Pooni as chief executive officer with immediate effect. With over 19 years experience in leading life science businesses, Kam joins Glyconics from Astellas Pharmaceutical Europe where he served as senior director of European commercial operations and effectiveness.